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Four possible diastereoisomers of 23,25,26-trihydroxyvitamin Ds were synthesized and compared with the 
natural metabolite. The 4 synthetic diastereoisomers could be separated into 4 peaks by high-performance 
liquid chromatography. The natural 23,25,26-trihydroxyvitamin Da comigrated with 23@),25(R),26- 
trihydroxyvitamin Ds. This result unequivocally demonstrates that the stereochemistry of the natural 
23,25,26-trihydroxyvitamin Ds has the 23(S) and 25(R) configuration. 
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1. INTRODUCTION 
It is now well established that vitamin D3 re- 
quires metabolic activation before it can mediate 
the biochemical events that result in increased 
calcium and phosphate absorption by the intestine 
and bone mineral mobilization [l]. The 25-hydro- 
xylation of vitamin D3 takes place in liver [2,3] and 
subsequently the further hydroxylation of 25-hy- 
droxyvitamin D3 (25-OH-D3) to lo,25-dihydroxy- 
vitamin D3 (la,25(OH)2D$ [4-61, 24,25-dihydro- 
xyvitamin D3 (24,25(08)2D3) [7-91, 25,26-dihy- 
droxyvitamin D3 (25,26(OH)~D3) [IO], 23,25-dihy- 
droxyvitamin D3 (23,25(OH)zDs) [ 1 1 - 131, and 
25-hydroxyvitamin D3-26,23-lactone (25OH- 
D3-26,23-lactone) [14-161 takes place in kidney 
and elsewhere. 
A new metabolite of vitamin D3 has been 
isolated from the incubation mixtures after 
25-OH-D3 was incubated with la,25(OH)zD3 sup- 
plemented chick kidney homogenates and from the 
serum of rats given large doses of vitamin D3 and 
identified as 23,25,26_trihydroxyvitamin D3 
(23,25,26(OH)sD3) [17]. Moreover, this metabolite 
is an intermediate in the biosynthesis of 25-OH- 
D3-26,23-lactone [16,18]. Although 23,25,26- 
(OH)sD3 has 4 possibIe stereochemical configura- 
tions at C-23 and C-25 positions, the stereoche- 
mistry of the natural 23,25,26(OH)~Ds is still 
unknown. 
We now report the definite determination of the 
stereochemical configuration of the natural 23,25, 
26(OH)sD3 to be 23(5’),25@),26(OH)3D3. 
* To whom correspondence should be addressed 2. MATERIALS AND METHODS 
Abbreviations: 25-OH-D3, 25-hydroxyvitamin Ds; 2425 
(OH)2D3, 24,25_dihydroxyvitamin Ds; 23,25(OH)zDs, 
23,25_dihydroxyvitamin D3; 25,26(OH)~Dp, 25,26- 
dihydroxyvitamin D3; lcu,25(OH)~Ds, lcu,25_dihydroxy- 
vitamin D3; 25-OH-Ds-26,23-lactone, 25-hydroxy- 
vitamin D3-26,23-lactone; 23,25,26(OH)sDs, 23,25,26- 
trihydroxyvitamin D3 
2.1. Syntheses of 4 stereoisomers of 23,25, 
26(OH.& 
Four stereoisomers of 25-OH-D3-26,23-lactone 
were synthesized as in [19]. 23@),25(@,26(OH)sD3 
was synthesized as follows. To 1OOpg 23(s), 
25(R)-25-OH-D3-26,23-lactone in 1 ml absolute 
tetrahydrofuran was added 1 mg LiAIHd. The 
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reaction was stirred at room temperature for 
60 min and then 2 ml water was added to ter- 
minate the reaction. The products were extracted 
with 2 ml ethylacetate twice and then were chro- 
matographed on high-performance liquid chroma- 
tography (HPLC) using a 4.6 x 250 mm Zorbax 
Sil column (Du Pont) eluted with 15% isopropanol 
in n-hexane at 1 ml/min. The 23(&25@),26- 
(OH)3D3 peak was eluted at a retention time of 
19.1 min. In the same manner, 1OOpg of 
23(2?),25(S)-25OH-Ds-26,23-la&one, 23(5),25(s)- 
25-OH-D3-26,23-lactone and 23@),25(@25- 
OH-D3-26,23-lactone ach were reacted with 1 mg 
LiAII&. According to these procedures, the total 
amounts of synthesized compounds were as 
follows: 23(~,25(~),26(OH)3D3, 19.6 pg; 23(R), 
25(S),26(OIGD3, 18.4 pg; 23(5X25(&26 
(OH13D3, 20.4 pg; 23(R),25(R),26(OH)3D,, 
20.6 ,ug. 
2.2. Preparution and pur~icution of 23,2.5,26- 
(OH)3Ll3 in rat serum 
Male weanling Wistar rats were fed a normal 
vitamin Ds-containing diet (Nippon Clea Corp. 
CE-2; Ca, 1.0%; P, 1.0%; vitamin Ds, 
2000 IV/kg) for 8 weeks ad libitum. The 150 rats 
were then dosed intr~us~ul~ly, each with 4 x 
10’ IU vitamin DJ in 100~1 ethanol, and after 3 
days, they were again dosed intramuscularly, each 
with 4 x 10’ IU vitamin D3 in 100~1 ethanol. 
Three days after this dose, the rats were anesthetiz- 
ed with ether and their blood was withdrawn from 
the abdomin~ aorta. The serum (600 ml) was 
diluted with the same volume of water and ex- 
tracted with 2 vol. in vitro of chloroform : metha- 
nol (1: 1). The chloroform extract of serum was 
chromatographed on a Sephadex LH-20 column 
(1.5 x 25 cm) e&ted with chloroform: n-hexane 
(65 : 35). The 23,25,26(OH)sDs fraction was 
isolated and purified by HPLC equipped with a 
Zorbax Sil column (4.6 x 250 mm) eluted with 
20% isopropanol in n-hexane as in [ 171. 
2.3. Preparation and par~f~cation f radioactive 
23,25,26(0E_i;lsD3 from in vitro incubation Of 
chick kidney homogenates 
One-day-old White Leghorn cockerels were fed 
a vitamin D-deficient diet [20] for 6 weeks, and 
then they were given orally 2 ,ug 1~,25(OH)zD3 dai- 
ly for 10 days. The chicks were sacrificed, their 
322 
kidneys were taken and 10% tissue homogenate in 
0.25 M sucrose was prepared with the aid of a 
Potter-Elvehjem homogenizer fitted with a Teflon 
pestle. To 24 ml homogenate (13 mg protein/~) 
in a 300 ml flask was added 56 ml reaction mixture 
containing 30 mM Tris-HCl (pH 7.4), 3.6 mM 
MgC12, 50 mM sucrose and 20 mM sodium suc- 
cinate as in [21]. The incubation was initiated by 
addition of 30 &i [26,27-~et~y~-3H]25-OH-D~ 
(9.7 Cilmmol) in 0.5 ml ethanol. The incubation 
was carried out at 37°C for 60 min with shaking. 
Chloroform: methanol (1: 1, v/v, 160 ml) was 
added to terminate the reaction. The metabolite 
23,25,26(OH)sD~ was separated and purified by 
Sephadex LH-20 column chromato~aphy and 
HPLC as in 1171. 
2.4. Compounds 
We synthesised the 4 stereoisomers of 25-OH- 
D3-26,23-la&one and lcru,25(OH)2Ds as in [ 19,221. 
Vitamin D3 was obtained from Sigma Chemicals 
(Chicago IL). [26,27-methyZ-3H]25-OH-D3 (spec. 
act. 9.7 Ci/mmol) was purchased from Amersham 
(Bucks). 
2.5. rnst~~e~ts 
HPLC was performed with a Hitachi Model 
635A equipped with a 264 nm ultraviolet detector 
and a 4.6 x 250 mm Zorbax Sil column. The 
mobile phase was 15(rlo isopropanol in n-hexane at 
1 ml/min. The radioactivity was measured with a 
Packard Tri-Carb liquid scintillation counter 
Model 3255 using an external standard. 
3. RESULTS 
The resolution of 4 diastereoisomers of 
23,25,26(0H)3D3 was performed by HPLC on a 
Zorbax Sil column using a mobile phase of 15% 
isopropanol in n-hexane. The retention time was 
14.8 min for 23@),25@),26(OH)3D3, 16.0 min for 
23(R),25@),26(OH)3D3, 17.1 min for 23(s),25(s), 
26(OH)3D3 and 19.1 min for 23@,25(R), 
26(OH)sD3, respectively (fig. 1A). The same reten- 
tion times were also recorded when injecting the 4 
diastereoisomers separately. The 23,25,26(OH)sD3 
isolated from the serum of rats clearly comigrated 
with the authentic 23(S),ZS(RXX(OH),D3 
(fig. 1B). The [26,27-methyl-3H]23,25,26(OH)3D3 
generated by in vitro incubation of [26,27+nethyl- 
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Fig. 1. High-performance liquid chromatographic 
profiles of diastereoisomers of synthetic 
23,25,26(OH)sDs and natural 23,25,26(OH)sD3: (A) 4 
diastereoisomers of synthetic 23,25,26(0H)sD3; (B) 
natural 23,25,26(OH)pDs from rat serum; (C) natural 
[26,27-methyf-3H]23,25,26(OH)sDs generated by in 
vitro incubation of [26,27-methyl-3H]25-OH-D3 with 
lcu,25(OH)zD3-supplemented chick kidney 
homogenates. 23,25,26(OH)sD~ was subjected to high- 
performance liquid chromatography on a 4.6 x 250 mm 
Zorbax Sil column eluted with 15% isopropanol in n- 
hexane at I ml/min. Arabic numerals in (A) indicate 
elution positions of 4 isomers of authentic 
23,25,26(OH)3Ds: (1) 23@),25@?),26(OH)sD3; (2) 
23@?),250,26(OH)sDs; (3) 23(s),25(%26(OH)sDs; (4) 
23(,9),25(I?),26(OH)sD3. The bars in the figure represent 
the radioactivity of each fraction. 
3H]25-OH-Ds with lo,25(0H)sDs-supplemented 
chick kidney homogenates also comigrated with 
the authentic 23@),25(R),26(OH)sDs (fig.lC). 
Recovery for the radioactivity was 86%. 
4. DISCUSSION 
To prove unequivocally the absolute configura- 
tion of the natural 23,25,26(0H)sD3, we compared 
the HPLC elution times of the natural metabolite 
and the synthetic 4 diastereoisomers of 23,25, 
26(OH)jDs. Our data unquestionably demonstrate 
that the naturally-occurring stereoisomer of 
23,25,26(OH)sDs has the 23(s) and 25(R) con- 
figuration. These data are further substantiated in 
[16,18] where 23,25,26(OH)sD3 was metabolized 
to 23(S),25(R)-25-OH-D3-26,23-lactone. 
It is possible that the 23,25,26(0H)sD3 can arise 
from 23,25(OH)~D3 [ll] or 25,26(OH)zDs 1231, a 
metabolite of vitamin Ds. The stereochemistry at 
the C-23 position of the natural 23,25(OH)zDs was 
determined to be the 23(s) configuration [12,13], 
and 23(S),25(OH)zDs is metabolized to 23,25, 
26(OH)sD3 [18], On the other hand, 25,26(OH)zDs 
possesses the 25(S) absolute configuration [24]. 
With 25(5),26(OH)zDr as a precursor, stereo- 
chemical inversion of the hydroxyl group at the 
C-25 position must occur during the course of C-23 
hydroxylation. Thus it might be more reasonable 
to consider that 23@),25(R),26(OH)sD, is produc- 
ed from 23(5’),25(OH)zDs. 
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